Latest in Gear

Image credit: Matthew Lloyd/Bloomberg via Getty Images

Apple entices its first big drug company to ResearchKit

The PARADE study will focus on 300 patients suffering with rheumatoid arthritis.
Matt Brian, @m4tt
07.18.16 in Mobile
638 Shares
Share
Tweet
Share
Save
Matthew Lloyd/Bloomberg via Getty Images

Although Apple's ResearchKit is almost two years old, the platform has mainly been reserved for clinical studies hosted by universities and medical researchers. Hundreds of thousands of people are already contributing data for studies focusing on asthma, diabetes, breast cancer, autism, epilepsy and melanoma, but now drugmakers are getting in on the act. Almost a year after it said it was readying studies using Apple's health data-collecting tool, GlaxoSmithKline (GSK) has confirmed the launch of a new research app to help monitor patients with rheumatoid arthritis.

GSK's Patient Rheumatoid Arthritis Data from the Real World (PARADE) study is the first of its kind and is the first time a major pharmaceutical (or big pharma) company has embarked on such a project. PARADE is designed to look at the impact of rheumatoid arthritis on a patient's life, by using iPhone sensors to collect information on joint pain, fatigue and overall mood. GSK will track the activity and "quality of life measures" for 300 patients over a three-month period.

GSK Rheumatoid Arthritis

Although GSK uses over 40 different technologies to collect health data, ResearchKit allows doctors, scientists and researchers to collect data more regularly and accurately from patients via their iPhone. It's not testing a new treatment yet, but the company intends to use the data it collects to "develop medicines more effectively."

From around the web

ear iconeye icontext filevr